Personality Disorders
9 cases on [genuine one-line description of what this topic's real clinical territory covers] — choose a case below to open its full multi-voice debate.
A 24-year-old presents after her third self-harm crisis in eighteen months, referred for outpatient follow-up with an 11-week wait before psychotherapy starts. The disagreement isn't which drug -- it's whether a national guideline's case against medicating this diagnosis still holds during the gap before therapy is even available.
A patient protective of a hard-won open-water swimming season asks whether omega-3 fatty acids could treat her anger and impulsivity instead of the antipsychotic her psychiatrist is proposing. The disagreement isn't about her reasoning -- it's about whether two small, decades-old trials are strong enough evidence to build a treatment sequence around.
A single father on four psychotropics accumulated over fifteen years for BPD reports daytime sedation that's starting to interfere with parenting. The disagreement isn't whether to deprescribe -- it's which drug to taper first, and how many changes can safely happen at once.
A nursing student's dissociative flashback-like episodes have not responded to SSRIs or eighteen months of therapy. The disagreement is whether an open-label positive trial or a more rigorous, null-trending blinded one should carry more weight in the decision.
A rigid, rule-bound patient is referred at his wife's insistence after his PCP wondered whether 'OCD medication' might help. The disagreement is whether OCPD's actual evidence base -- a fraction of OCD's -- justifies the same pharmacologic approach the name similarity implies.
A warehouse worker's lifelong odd beliefs escalate to ideas of reference about coworkers sending him coded messages. Real trial evidence supports low-dose risperidone for exactly this symptom domain -- but the case for waiting rests on his current stability, and on an older tolerability literature weaker than the trial itself.
Court-mandated after an assault conviction, a man with antisocial personality disorder and heavy alcohol use is referred for 'anger treatment.' The disagreement is whether to medicate the aggression directly or redirect to the one diagnosis in the room that actually has evidence behind it.
A remote worker facing new in-office requirements is in crisis over evaluative anxiety that sits on the boundary between social anxiety disorder and avoidant personality disorder. The disagreement is what an SSRI can realistically be expected to reach -- the anxiety symptom, or the deeper trait-level pattern.
A patient stable for 24 years on lamotrigine for BPD is told, for the first time, that a large randomized trial found the drug no better than placebo. The disagreement is whether her own long course should outweigh a definitive population-level null result -- and who gets to decide.